Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 18Completed 11Active not recruiting 7Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 128Breast Neoplasms 111Neoplasms 93Neoplasm Metastasis 76Melanoma 70Colorectal Neoplasms 69Leukemia, Myeloid, Acute 66Prostatic Neoplasms 58Multiple Myeloma 53Lung Neoplasms 51Ovarian Neoplasms 49Squamous Cell Carcinoma of Head and Neck 45Recurrence 41Triple Negative Breast Neoplasms 40Carcinoma, Renal Cell 38Carcinoma, Hepatocellular 38Pancreatic Neoplasms 36Myelodysplastic Syndromes 36Glioblastoma 34Brain Neoplasms 34Stomach Neoplasms 30Lymphoma, Non-Hodgkin 30Lymphoma 30Endometrial Neoplasms 30Head and Neck Neoplasms 28Lymphoma, Large B-Cell, Diffuse 27Leukemia 27Uterine Cervical Neoplasms 26Cholangiocarcinoma 26Urinary Bladder Neoplasms 24

Interventions

Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Advanced Cancer × 1 year × Clear all
NCT03446040 2025-09-18

An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread

Bristol-Myers Squibb

Phase 1/2 Terminated
92 enrolled 31 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡